Search
Cyclophosphamide Treatment Options
A collection of 2180 research studies where Cyclophosphamide is the interventional treatment. These studies are located in the United States . Cyclophosphamide is used for conditions such as Breast Cancer, Lymphoma and Leukemia.
469 - 480 of 2180
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma
Recruiting
This phase I trial tests the side effects and best dose of TGFbi natural killer (NK) cells (TiNK) when given together with isatuximab for the treatment of patients with multiple myeloma that has come back after a period of improvement (relapsed) or that has not responded to treatment (refractory). NK cells are a type of white blood cell that are known to spontaneously attack cancer cells. TiNK are NK cells made in a laboratory to have a higher response to tumor cells. A monoclonal antibody is a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Split-Dose R-CHOP for Older Adults with DLBCL
Active Not Recruiting
This study is investigating a new administration schedule of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) chemotherapy for participants with Diffuse Large B-Cell Lymphoma (DLBCL), focusing on an underserved elderly population (aged 75 and up; certain participants 70-74 may be eligible) that is often excluded from clinical trials. Participants can expect to be on study for 2.5 years (treatment for 6 months and 2 years of post treatment follow-up).
Gender:
ALL
Ages:
70 years and above
Trial Updated:
03/21/2025
Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Conditions: Diffuse Large B Cell Lymphoma, DLBCL, Cancer
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Recruiting
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +37 locations
Conditions: Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B Cell Non-Hodgkin's Lymphoma
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
Recruiting
This is a Phase II clinical trial testing the use of two antigen-directed therapies, inotuzumab and blinatumomab, as part of induction therapy for children and young adults with newly diagnosed B-cell precursor acute lymphoblastic leukemia and lymphoma.
Primary Objective
* To assess if the flow-cytometry assessed MRD-negative remission rate following an immunotherapy-based Induction in NCI-high risk patients without favorable genetic features is higher than the results of similar patients trea... Read More
Gender:
ALL
Ages:
Between 1 year and 18 years
Trial Updated:
03/21/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
Active Not Recruiting
This phase II trial is studying the side effects of giving combination chemotherapy together with or without donor stem cell transplant and to see how well it works in treating patients with acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Giving chemotherapy and total-body irradiation be... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
03/20/2025
Locations: Banner University Medical Center - Tucson, Tucson, Arizona +156 locations
Conditions: Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Adult L1 Acute Lymphoblastic Leukemia, Adult L2 Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia
Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Active Not Recruiting
This phase II pilot trial studies the side effects and how well dinutuximab and sargramostim work when combined with chemotherapy in patients with high-risk neuroblastoma. Immunotherapy with monoclonal antibodies, such as dinutuximab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Sargramostim helps the body produce normal infection-fighting white blood cells. These cells also help the dinutuximab work better. Giving chemother... Read More
Gender:
ALL
Ages:
30 years and below
Trial Updated:
03/20/2025
Locations: Children's Hospital Los Angeles, Los Angeles, California +9 locations
Conditions: Ganglioneuroblastoma, High Risk Neuroblastoma
Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)
Terminated
The standard of care for children with DIPG includes focal radiotherapy (RT) but outcomes have remained dismal despite this treatment. The addition of oral Temozolomide (TMZ) concurrently with RT followed by monthly TMZ was also found to be safe but ineffective. Recent studies in adults have shown that certain types of chemotherapy induce a profound but transient lymphopenia (low blood lymphocytes) and vaccinating and/or the adoptive transfer of tumor-specific lymphocytes into the cancer patient... Read More
Gender:
ALL
Ages:
Between 3 years and 30 years
Trial Updated:
03/20/2025
Locations: UF Health Shands Children's Hospital, Gainesville, Florida
Conditions: Diffuse Intrinsic Pontine Glioma (DIPG), Brain Stem Glioma
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Subjects With Refractory Generalized Myasthenia Gravis
Recruiting
A Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Subjects with Myasthenia Gravis
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/20/2025
Locations: University of California, Irvine, Orange, California +10 locations
Conditions: Myasthenia Gravis, Generalized Myasthenia Gravis
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
Recruiting
This research study combines 2 different ways of fighting disease: antibodies and T cells. Both antibodies and T cells have been used to treat patients with cancers, and both have shown promise, but neither alone has been sufficient to cure most patients. This study combines both T cells and antibodies to create a more effective treatment. The treatment being researched is called autologous T lymphocyte chimeric antigen receptor cells targeted against the CD19 antigen (ATLCAR.CD19) administratio... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina
Conditions: Lymphoma, Lymphoma, B-Cell, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases
Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma
Recruiting
This phase Ib/II clinical trial tests the safety, side effects, and effectiveness of mosunetuzumab with chemotherapy for the treatment of patients with untreated, c-Myc rearrangement positive, high grade B cell lymphoma or diffuse large B cell lymphoma. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as mosunetuzumab, may help the bo... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/19/2025
Locations: OHSU Knight Cancer Institute, Portland, Oregon
Conditions: Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
Terminated
This study is being done to learn whether a new method to prevent rejection between the donor immune system and the patient's body is effective.
Gender:
ALL
Ages:
65 years and below
Trial Updated:
03/19/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Acute Lymphoid Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia
Active Not Recruiting
This phase II trial studies how well ibrutinib, fludarabine phosphate, cyclophosphamide, and obinutuzumab work in treating patients with chronic lymphocytic leukemia. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fludarabine phosphate and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spread... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
469 - 480 of 2180